Pharmaceuticals News

Pa-positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatmentOnly one exacerbation meeting the Hill/EMBARC...

Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...

Aggregated presentation by day and by market Weekly report on share repurchases from 31st August to 04th September 2026       Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code...

Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 31 août au 4 septembre 2026       Nom de l'émetteurCode identifiant de l'émetteur (code...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or...

Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE...

STEP Young data show 40.4% of children treated with semaglutide and lifestyle modification were no longer classified as having obesity.

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the...